Australian Clinical Labs Statistics
Total Valuation
ASX:ACL has a market cap or net worth of AUD 593.34 million. The enterprise value is 887.49 million.
Market Cap | 593.34M |
Enterprise Value | 887.49M |
Important Dates
The next estimated earnings date is Tuesday, August 26, 2025.
Earnings Date | Aug 26, 2025 |
Ex-Dividend Date | Mar 27, 2025 |
Share Statistics
ASX:ACL has 197.12 million shares outstanding. The number of shares has decreased by -0.78% in one year.
Current Share Class | n/a |
Shares Outstanding | 197.12M |
Shares Change (YoY) | -0.78% |
Shares Change (QoQ) | +2.12% |
Owned by Insiders (%) | 1.84% |
Owned by Institutions (%) | 63.34% |
Float | 173.53M |
Valuation Ratios
The trailing PE ratio is 19.60 and the forward PE ratio is 15.69. ASX:ACL's PEG ratio is 1.01.
PE Ratio | 19.60 |
Forward PE | 15.69 |
PS Ratio | 0.81 |
PB Ratio | 3.51 |
P/TBV Ratio | 152.45 |
P/FCF Ratio | 3.70 |
P/OCF Ratio | 3.55 |
PEG Ratio | 1.01 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.46, with an EV/FCF ratio of 5.53.
EV / Earnings | 28.94 |
EV / Sales | 1.22 |
EV / EBITDA | 4.46 |
EV / EBIT | 13.36 |
EV / FCF | 5.53 |
Financial Position
The company has a current ratio of 0.59, with a Debt / Equity ratio of 1.86.
Current Ratio | 0.59 |
Quick Ratio | 0.45 |
Debt / Equity | 1.86 |
Debt / EBITDA | 1.58 |
Debt / FCF | 1.96 |
Interest Coverage | 3.61 |
Financial Efficiency
Return on equity (ROE) is 18.56% and return on invested capital (ROIC) is 8.51%.
Return on Equity (ROE) | 18.56% |
Return on Assets (ROA) | 7.11% |
Return on Invested Capital (ROIC) | 8.51% |
Return on Capital Employed (ROCE) | 17.62% |
Revenue Per Employee | 148,627 |
Profits Per Employee | 6,259 |
Employee Count | 4,900 |
Asset Turnover | 1.25 |
Inventory Turnover | 27.75 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.36% in the last 52 weeks. The beta is 1.13, so ASX:ACL's price volatility has been higher than the market average.
Beta (5Y) | 1.13 |
52-Week Price Change | +23.36% |
50-Day Moving Average | 3.15 |
200-Day Moving Average | 3.27 |
Relative Strength Index (RSI) | 49.03 |
Average Volume (20 Days) | 958,074 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ASX:ACL had revenue of AUD 728.27 million and earned 30.67 million in profits. Earnings per share was 0.15.
Revenue | 728.27M |
Gross Profit | 265.75M |
Operating Income | 66.44M |
Pretax Income | 46.31M |
Net Income | 30.67M |
EBITDA | 79.99M |
EBIT | 66.44M |
Earnings Per Share (EPS) | 0.15 |
Balance Sheet
The company has 21.57 million in cash and 315.32 million in debt, giving a net cash position of -293.75 million or -1.49 per share.
Cash & Cash Equivalents | 21.57M |
Total Debt | 315.32M |
Net Cash | -293.75M |
Net Cash Per Share | -1.49 |
Equity (Book Value) | 169.11M |
Book Value Per Share | 0.85 |
Working Capital | -85.67M |
Cash Flow
In the last 12 months, operating cash flow was 167.16 million and capital expenditures -6.68 million, giving a free cash flow of 160.47 million.
Operating Cash Flow | 167.16M |
Capital Expenditures | -6.68M |
Free Cash Flow | 160.47M |
FCF Per Share | 0.81 |
Margins
Gross margin is 36.49%, with operating and profit margins of 9.12% and 4.21%.
Gross Margin | 36.49% |
Operating Margin | 9.12% |
Pretax Margin | 6.36% |
Profit Margin | 4.21% |
EBITDA Margin | 10.98% |
EBIT Margin | 9.12% |
FCF Margin | 22.03% |
Dividends & Yields
This stock pays an annual dividend of 0.12, which amounts to a dividend yield of 4.07%.
Dividend Per Share | 0.12 |
Dividend Yield | 4.07% |
Dividend Growth (YoY) | 25.00% |
Years of Dividend Growth | n/a |
Payout Ratio | 77.78% |
Buyback Yield | 0.78% |
Shareholder Yield | 4.85% |
Earnings Yield | 5.17% |
FCF Yield | 27.05% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
ASX:ACL has an Altman Z-Score of 2.65. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.65 |
Piotroski F-Score | n/a |